Affimed N.V. (NASDAQ:AFMD) was downgraded by stock analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a research note issued to investors on Friday.

A number of other research firms have also recently commented on AFMD. Oppenheimer Holdings, Inc. set a $10.00 price target on shares of Affimed N.V. and gave the company a “buy” rating in a report on Thursday, May 18th. SunTrust Banks, Inc. began coverage on shares of Affimed N.V. in a report on Thursday, July 13th. They set a “buy” rating and a $7.00 price target on the stock. Finally, Jefferies Group LLC reiterated a “hold” rating and set a $2.50 price target on shares of Affimed N.V. in a report on Thursday, July 27th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the company’s stock. Affimed N.V. presently has a consensus rating of “Hold” and an average target price of $4.80.

Affimed N.V. (NASDAQ AFMD) traded up 3.14% during trading on Friday, reaching $2.05. The company’s stock had a trading volume of 270,729 shares. The company has a 50-day moving average of $2.14 and a 200 day moving average of $2.24. The firm’s market cap is $90.07 million. Affimed N.V. has a one year low of $1.65 and a one year high of $3.19.

Affimed N.V. (NASDAQ:AFMD) last posted its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.20) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.22) by $0.02. Affimed N.V. had a negative net margin of 978.31% and a negative return on equity of 73.85%. The firm had revenue of $0.51 million for the quarter, compared to analysts’ expectations of $1.31 million. During the same quarter in the prior year, the company posted ($0.24) earnings per share. The business’s revenue for the quarter was down 75.4% on a year-over-year basis. Analysts expect that Affimed N.V. will post ($0.84) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This article was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.watchlistnews.com/affimed-n-v-afmd-downgraded-to-strong-sell-at-valuengine/1536873.html.

A number of large investors have recently modified their holdings of the company. Wellington Management Group LLP boosted its stake in shares of Affimed N.V. by 30.8% in the first quarter. Wellington Management Group LLP now owns 5,413,291 shares of the biopharmaceutical company’s stock valued at $12,450,000 after buying an additional 1,274,852 shares in the last quarter. NEA Management Company LLC bought a new stake in shares of Affimed N.V. during the first quarter valued at about $8,944,000. Tekla Capital Management LLC boosted its stake in shares of Affimed N.V. by 377.7% in the first quarter. Tekla Capital Management LLC now owns 1,405,324 shares of the biopharmaceutical company’s stock valued at $3,232,000 after buying an additional 1,111,111 shares in the last quarter. Nationwide Fund Advisors boosted its stake in shares of Affimed N.V. by 4.6% in the second quarter. Nationwide Fund Advisors now owns 506,199 shares of the biopharmaceutical company’s stock valued at $1,038,000 after buying an additional 22,172 shares in the last quarter. Finally, Virtu KCG Holdings LLC bought a new stake in shares of Affimed N.V. during the second quarter valued at about $144,000. Institutional investors own 42.34% of the company’s stock.

About Affimed N.V.

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells.

Receive News & Ratings for Affimed N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed N.V. and related companies with Analyst Ratings Network's FREE daily email newsletter.